Glenmark Pharmaceuticals is confident of outlicensing at least one of its new chemical entities (NCEs) under development before the end of this financial year. Glenmark has six molecules under development. Its Crofelemer, an anti-diarrheal molecule under development, is now in Phase-III of clinical trials, with plans for a launch in developing countries by next year. Eli Lilly, which had in-licensed an osteoarthritis and pain molecule from Glenmark, also had suspended further development in October 2008.